Severity
Moderate
ModerateClass IIOngoing
FDA Drug recall · Reported July 1, 2026
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Direct Rx recalled DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Cap… - a moderate-severity action.
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Cap… was recalled by Direct Rx in July 1, 2026. Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Check the official notice for the remedy. Verify recall #D-0617-2026 with the FDA Drug before acting.
The recall
Direct Rx issued this moderate-severity FDA Drug recall-CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
- Moderate
- severity level
- Class II
- classification
- July 1, 2026
- reported
Sourced from official FDA Drug enforcement records. Verify recall #D-0617-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
Recall Insight
This FDA Drug action (record #D-0617-2026) was formally reported on July 1, 2026, with the manufacturer initiating the action on June 22, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Direct Rx is listed as the recalling firm, operating out of Dawsonville, GA. Federal records list the affected scope as 263 Bottles.
The documented reason for this recall is: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Distribution data in the federal record shows the product reached: U.S. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Drugs & Medications recalls over time
Where this recall sits in its category - 14,436 drugs & medications recalls on record
Of 88,001 recalls with an agency hazard classification, 19,020 are high severity, 64,468 moderate, and 4,513 low. A further 16,157 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Affected scope
263 Bottles
Related Recalls
6
6 from same agency
Product description
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Recall Profile
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0617-2026 |
| Date reported | July 1, 2026 |
| Date initiated | June 22, 2026 |
| Recalling firm | Direct Rx |
| Firm location | Dawsonville, GA |
| Affected scope | 263 Bottles |
| Distribution | U.S. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
- Check the recall number (D-0617-2026) and product description against the item you own. Search the archive
- Confirm the current status with FDA Drug before acting, recall details can be updated.
- Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Frequently Asked Questions
What product was recalled? ▼
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.. Recalled by Direct Rx. Units affected: 263 Bottles.
Why was this product recalled? ▼
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Which agency issued this recall? ▼
This recall was issued by the FDA Drug on July 1, 2026. Severity: Moderate. Recall number: D-0617-2026.
Where was the recalled product distributed? ▼
Distribution: U.S. Nationwide.
How do I check if my product is affected by a recall? ▼
Check the product description and recall number (D-0617-2026) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device? ▼
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.
Nationwide recalls with similar severity or category timing
Two federal-filing-derived peer sets for this notice, both outside the same recalling firm and filing state so the neighborhoods are not firm or geographic containment.
Similar severity · nearest report date
Same archive severity grade (Moderate), closest by report date among other firms and states.
Similar Drugs & Medications · nearest report date
Same product category, closest by report date among other firms and states (deduped against the severity set).
Nearby Recalls in This Category
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Showing 5 of 14436 other recalls in this category.
FDA Drug Moderate
Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 90, 0.2%), Sterile 0.4 FL OZ (13 mL)…
Rohto-Mentholatum (Vietnam) Co., Ltd. · 2026-07-29
FDA Drug Moderate
Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Packa…
Major Pharmaceuticals · 2026-07-29
FDA Drug Moderate
Rohto Cooling Eye Drops Cool Relief (naphazoline hydrochloride 0.012%, polysorbate 80 0.2%), Sterile, 0.4 FL OZ (13 mL)…
Rohto-Mentholatum (Vietnam) Co., Ltd. · 2026-07-29
FDA Drug Moderate
Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Pac…
Major Pharmaceuticals · 2026-07-29
FDA Drug Moderate
Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Pac…
Major Pharmaceuticals · 2026-07-29
Compare this recall with Rohto Cooling Eye Drops Max Strength (naphazoline hydrochlo… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 1, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.